Back to search results

MICABO-ALS Trial: Antioxidants for ALS

This study is testing a combination of over-the-counter antioxidants (vitamin E, NAc cysteine, L-cystine, Nicotinamide, and Taurursodiol) for people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if these antioxidants, which are thought to help with oxidative stress (a major cause of ALS), can slow or stop the disease's progression. This trial aims to confirm findings from a previous study and expand on them by using higher doses of these safe compounds. You may be able to join if you are 21 to 80 years old and have a confirmed diagnosis of ALS. The study will measure a substance in your blood called NfL at 12 months to see if the treatment is working. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 60 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 months, which suggests follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04244630

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Active, Not Recruiting
PHASE2Ages 21–80InterventionalTreatment
Dallas VA Medical Center
~21 participants
Updated 2026-09-02 on ClinicalTrials.gov
What's tested:Antioxidants

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measurement of serum NfL
Measured over 12 months

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Explore related trials

Amyotrophic Lateral Sclerosis

NCT04244630

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • VA North Texas Health Care System

    Dallas, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Olaf Stuve, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Dallas VA Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Measurement of serum NfL12 months

    The change in log serum NfL level from baseline to 12 months will be assessed using a linear mixed model and the differences in NfL level at 12 months from baseline assessed using a paired t-test.